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Ongoing progress in the field of regenerative medicine, in combi-
nation with the development of tissue-
engineered skin products, has opened 
new possibilities for the treatment of 
certain diseases in which current treat-
ments are aimed at alleviating symp-
toms but are not able to get a permanent 
cure. Our laboratory has developed a 
fibrin-based bioengineered human skin
that has been successfully used for per-
manent regenerative therapies in differ-
ent situations in the clinic. Moreover, 
we have been able to stably regenerate 
human skin by orthotopic grafting of 
this skin equivalent onto the back of 
immunodeficient mice. The so-called 
skin-humanized mouse model system 
has permitted us to model several mono-
genic skin diseases, when keratinocytes 
and fibroblasts harboring the genetic 
defect were used. In most cases differ-
ent gene therapy approaches for ex vivo 
correction of cells have proved effective 
in reverting the phenotype using this 
model. More importantly, the feasibility 
of the system has allowed us to generate 
a skin humanized mouse model for pso-
riasis, a common chronic inflammatory 
disease where the immune component 
has a pivotal role in the pathogenesis. 
Establishing reliable humanized animal 
models for skin diseases is necessary to 
gain a deeper knowledge of the patho-
genesis and to develop novel therapeu-
tic strategies. In this sense, the skin 
humanized mouse model developed in 
our laboratory meets the needs of this 
field of research.
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Skin is the largest organ of the body and 
accounts for about 15 percent of adult 
body weight. It confers protection against 
trauma and foreign chemical and bio-
logical substances and provides impor-
tant functions contributing to maintain 
homeostasis. Loss of skin integrity can 
compromise a patient’s quality of life and 
in severe cases can even lead to further 
medical complications resulting in major 
disability or death.
The accessibility of skin has made this 
organ an interesting target for replace-
ment therapies over the past decades. 
Tissue expansion and development of 
substitutes have been commonly used 
in reconstructive surgery to restore skin 
structure and function in patients suf-
fering traumatic injuries with significant 
skin losses. Moreover, tissue engineered 
skin may result in multiple benefits for 
patients showing several skin conditions 
such as chronic non-healing wounds 
associated with diabetes or vascular 
disorders.
In some monogenic skin diseases, such 
as severe cases of Epidermolysis Bullosa 
(EB), the skin integrity is severely com-
promised and patients present a high risk 
of developing skin cancer. Intensive multi-
disciplinary care and surgical procedures 
constitute the only alternative for these 
patients to relieve symptoms and prevent 
malignant transformation. Gene therapy 
in combination with tissue engineering 
represents a promising therapeutic option 
for these patients.
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situations, such as extensive burns, necro-
tizing fasciitis, removal of giant nevi and 
graft-versus-host disease3,5 (Fig. 1).
Some of the advantages of autolo-
gous cell sourcing include the absence of 
immune reaction in the host and eliminat-
ing the need for immunosuppressive ther-
apies. However, chimerical bioengineered 
skin containing autologous keratinocytes 
and allogeneic fibroblasts has been shown 
to be clinically valuable in asisting wound 
healing in Dystrophic Epidermolysis 
Bullosa (EBD). This new product has 
been granted the Orphan Drug designa-
tion by the EMEA (orphan designation 
number EU/306/369).
Completely allogeneic bioengineered 
skin has been shown to be benefical in 
the treatment of chronic wounds, where 
permanent engraftment is not needed but 
the skin behaves as a healing device that 
contributes to enhance the patient’s own 
repair process.
skin regeneration.1 In patients with severe 
skin losses there is an unavoidable need 
for the production of large-scale compos-
ite skin equivalents. We have developed an 
improved and autologous bioengineered 
skin based on the use of clotted human 
plasma as a three-dimensional dermal scaf-
fold in which fibroblasts are embedded. 
We have demonstrated that this plasma-
based dermal equivalent provides excellent 
keratinocyte growth support.2 As a result, 
experimental grafting in immunodeficient 
mice yielded a healthy and mature skin 
with human architecture that persisted 
even after several epidermal turn-overs 
took place, as demonstrated immunohis-
tochemically during long-term follow-up 
periods.3,4 Preservation of the epidermal 
cell stemness is a requisite for perma-
nent skin regeneration. We have success-
fully used this bioengineered human skin 
(World Patent WO/2002/072800) in the 
clinics for permanent coverage in several 
Therapeutic management and drug 
development in other common chronic 
inflammatory skin disorders, such as pso-
riasis and atopic dermatitis (AD), largely 
depend on the characterization of the 
molecular pathways contributing to the 
pathogenesis of these complex diseases.
Modeling skin diseases in a humanized 
context is fundamental to acquire basic 
knowledge about mechanisms of disease 
and enables preclinical studies that will 
have a potentially positive impact on the 
clinical outcome.
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Present culture technologies enable opti-
mal in vitro expansion of cells obtained 
from skin biopsies that can be assembled 
in three-dimensional matrices to engineer 
skin equivalents suitable for clinical use. A 
large list of natural scaffolds and synthetic 
materials have been developed to date for 
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the cancer-prone disease Xeroderma 
Pigmentosum (XP).18 Regenerated human 
skin obtained by orthotopic grafting of 
bioengineered cutaneous equivalents con-
taining collagen VII-null RDEB kerati-
nocytes showed histological evidence of 
extensive blistering as observed in skin 
biopsies from RDEB patients. A complete 
and permanent reversion of this pheno-
type was achieved when RDEB epidermal 
stem cells used in the generation of the 
skin equivalents were genetically modi-
fied by using retroviral vectors encoding 
human collagen type VII.15 Characteristic 
histological features of NS were also dem-
onstrated after grafting human NS bio-
engineered skin onto immunodeficient 
mice. Reversal of the skin abnormalities 
was attained after using a lentiviral vector 
to direct SPINK5 expression in keratino-
cytes.17 We have also established a photo-
sensitive humanized skin model through 
the grafting of bioengineered skin con-
taining XP-C patient cells. The XP kera-
tinocyte deficiency in nucleotide excision 
repair (NER) was evidenced in vivo after 
acute UVB irradiation.18
Gene therapy approaches in com-
bination with the bioengineered skin-
humanized mouse model constitute a 
robust platform to conduct preclinical 
studies. However, the use of spontane-
ous immunocompetent animal models 
for genodermatoses will be relevant as a 
complementary tool to evaluate the poten-
tial adverse immune response that can be 
mounted by the host after introducing for-
eign therapeutic genes. This is particularly 
critical in the case of null-mutation carri-
ers.16,19,20 In other cutaneous disorders pre-
senting dominant negative mutations that 
lead to aberrant protein expression, an 
alternative to a replacement gene therapy 
option must be sought, either by prevent-
ing mutant gene expression or by overex-
pressing the normal gene product.
??? ???????????????????
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Inflammatory and autoimmune cutane-
ous disorders constitute a major health 
and social problem around the world. 
Sometimes they may be disfiguring and 
disabling and have a direct impact on 
patient’s psychological distress. Skin 
bioengineered skins capable of deliver-
ing, in a time-controlled fashion, critical 
growth factors and/or cytokines for scar-
free tissue repair such as those involved 
in embryonic skin regeneration. As a first 
attempt, the combination of cell- and 
genetic-based therapies has made it pos-
sible to evaluate the promoting or detri-
mental wound-healing activities of specific 
factors using different model systems, such 
as transgenic mice, KO-mice or xenograft 
models.9-11 As a proof of concept, we have 
selected KGF, a well-characterized factor 
that is differentially regulated in normal 
and impaired healing, to compare the effi-
cacy of different transient gene transfer 
strategies aimed at delivering smart factors 
to promote cutaneous repair in the wound 
healing skin-humanized model.12,13
Developing new in vivo models of 
impaired wound healing may better pro-
vide reliable platforms resembling human 
chronic wounds to test the healing-pro-
moting activities of different molecules. 
Diabetic foot ulcerations constitute a 
major public health concern. Leptin-
deficient ob/ob mice have been widely used
as a model of diabetes impaired-wound
healing. Thus, we took advantage of this 
model system in order to test the repair-
promoting activities of the pleiotropic fac-
tor LL-37 antimicrobial peptide, which 
has been shown to improve the repair pro-
cess as stated above, in addition to its role 
in defense processes. We used an adeno-
viral-mediated gene transfer approach to 
overexpress this factor around wound mar-
gins of full-thickness wounds generated in 
this animal model, and demonstrated that 
LL-37 increased the re-epithelialization 
rate and granulation tissue formation in a 
healing-impaired situation.14
Our work is currently focused on 
generating a humanized animal model 
of impaired wound healing, by inducing 
experimental diabetes in the well-charac-
terized skin-humanized mice using strep-
tozotocin injection (Martínez-Santamaria 
et al. manuscript in preparation).
The skin-humanized mouse model has 
also been very useful in recreating dif-
ferent human monogenic skin diseases 
(Fig. 1), such as the mechano-bullous dis-
ease,15,16 the Netherton Syndrome (NS), an 
epidermal differentiation disorder caused 
by mutations in the SPINK5 gene,17 and 
To favor the efficacy of autologous 
bioengineered skin substitutes in engraft-
ment, it is necessary to improve wound 
bed conditioning. Infection is one of the 
major causes of graft rejection and this is 
critical in immunocompromised patients 
presenting with severe and extensive 
burns, leading to further complications 
and even death. Antimicrobial peptides 
(AMPs) appear as an attractive alternative 
to the use of conventional antibiotics, as 
they present microbicidal activity against 
a broad spectrum of pathogens and low-
level resistance. Some of them have also 
been shown to increase the repair process. 
We have shown efficient antimicrobial 
activity of AMPs gene-transduced kera-
tinocytes forming part of the epidermal 
component in a human skin equivalent.6 
Cutaneous tissue engineering in combi-
nation with antimicrobial gene therapies 
emerges as a promising strategy to improve 
wound coverage and combat infection at 
the same time.
???????? ????? ???? ????????
We have generated a skin-humanized 
mouse model based on the permanent 
engraftment of a bioengineered human 
skin onto the back of immunodefi-
cient mice.3,7 It consists of a chimeric 
model in which a skin of human origin 
is regenerated, vascularized and inner-
vated by mouse vessels and nerves. One 
of the main advantages of this method 
is that the generation of a large number 
of engrafted mice containing a signifi-
cant area of homogeneous single donor-
derived human skin would be available 
in a relatively short period of time. The 
functionality of this mature and quiescent 
human skin has been also demonstrated, 
with the main features of a human physi-
ological process, such as wound healing 
having been accurately recreated in the 
context of physiologic acute human exci-
sional wounds.8 This model also offers 
the possibility of using in vitro genetically 
manipulated human keratinocytes and/or 
fibroblasts during the amplification proce-
dure, either to overexpress or silence spe-
cific genes, thus generating transgenic or 
KO humanized-skin respectively.
One of the main challenges in regen-
erative medicine is to create smart 
?
severe skin losses to chronic wounds of 
different origin. Nowadays, a merge of 
skin bioengineering and gene therapy is 
envisioned as the ultimate regenerative 
medicine advance towards treatment of 
some monogenic inherited skin disorders. 
Our group has contributed to the skin bio-
engineering discipline through the devel-
opment of a new skin substitute based 
on the use of fibroblasts embedded in a 
three-dimensional dermal scaffold made 
of clotted human plasma. The special 
characteristics of this plasma-based der-
mal equivalent, in terms of keratinocyte 
growth support and stem cell preserva-
tion, have allowed its successful use in the 
clinics for permanent skin replacement in 
several situations. However, future chal-
lenges remain concerning the clinical 
outcome from a cosmetic and performing 
point of view. Some important issues need 
to be solved, such as the regeneration of a 
fully functional skin containing append-
ages (hairs, sweat glands and sebaceous 
glands) and to attain scar-free remodel-
ling features as seen in embryonic wound 
repair. At the preclinical level, we have 
been able to develop a skin humanized 
animal model that recreates various skin 
conditions of genetic origin by grafting 
patient-derived bioengineered skin onto 
immunodeficient mice. More recently, we 
have also been able to model a complex 
inflammatory skin disease, such as pso-
riasis, by introducing specific cytokines 
and/or immune cell subpopulations in 
this model. The versatility of the system, 
which includes the possibility of human 
skin regeneration with genetically modi-
fied cells, greatly expands the range of 
possibilities for studying innovative thera-
peutic approaches and the contribution of 
different factors/signalling pathways to 
specific dermatological entities.
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